Nxera Pharma Co (TYO:4565) partner Neurocrine Biosciences has initiated a Phase 3 trial for NBI-1117568, an oral muscarinic M4 receptor agonist, for treating schizophrenia, according to a Thursday filing on the Tokyo Stock Exchange.
The trial follows positive Phase 2 results reported in August 2024, showing a significant reduction in symptoms.
The global, placebo-controlled trial will enroll around 280 patients with acute schizophrenia symptoms. The primary endpoint is the reduction of PANSS score, with secondary endpoints focusing on clinical severity.
No milestone payment is due at trial start, but a $15 million payment will be triggered when the first patient is dosed.
Price (JPY): $934.00, Change: $+18, Percent Change: +1.97%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。